Compare PRMB & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PRMB | KNSA |
|---|---|---|
| Founded | 1955 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.0B | 7.7B |
| IPO Year | 2025 | 2018 |
| Metric | PRMB | KNSA |
|---|---|---|
| Price | $23.33 | $93.77 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 7 |
| Target Price | $28.36 | ★ $111.57 |
| AVG Volume (30 Days) | ★ 5.6M | 800.1K |
| Earning Date | 11-05-2026 | 10-27-2026 |
| Dividend Yield | ★ 2.06% | N/A |
| EPS Growth | ★ 328.57 | 225.00 |
| EPS | 0.60 | ★ 1.14 |
| Revenue | ★ $6,664,000,000.00 | $677,564,000.00 |
| Revenue This Year | $2.65 | $54.80 |
| Revenue Next Year | $3.45 | $28.50 |
| P/E Ratio | ★ $38.78 | $82.02 |
| Revenue Growth | 29.34 | ★ 60.09 |
| 52 Week Low | $14.80 | $37.02 |
| 52 Week High | $26.21 | $99.31 |
| Indicator | PRMB | KNSA |
|---|---|---|
| Relative Strength Index (RSI) | 63.01 | 55.90 |
| Support Level | $23.42 | $87.30 |
| Resistance Level | $23.78 | $98.90 |
| Average True Range (ATR) | 0.89 | 4.01 |
| MACD | 0.12 | -0.45 |
| Stochastic Oscillator | 72.32 | 54.29 |
Primo Brands Corp is a North American branded beverage company focused on healthy hydration. It delivers sustainably and domestically sourced diversified offerings across products, formats, channels, price points, and consumer occasions, distributed in every state and Canada. Primo Brands is in reusable packaging, helping to reduce waste through its reusable, multi-serve bottles and brand packaging portfolio, which includes recycled plastic, aluminum, and glass.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.